JP2016506962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506962A5 JP2016506962A5 JP2015556106A JP2015556106A JP2016506962A5 JP 2016506962 A5 JP2016506962 A5 JP 2016506962A5 JP 2015556106 A JP2015556106 A JP 2015556106A JP 2015556106 A JP2015556106 A JP 2015556106A JP 2016506962 A5 JP2016506962 A5 JP 2016506962A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- compound according
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical group 0.000 claims 25
- 229910052799 carbon Inorganic materials 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 125000001424 substituent group Chemical group 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000006413 ring segment Chemical group 0.000 claims 10
- -1 amino, protected amino Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 150000001204 N-oxides Chemical class 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361757942P | 2013-01-29 | 2013-01-29 | |
| US61/757,942 | 2013-01-29 | ||
| PCT/US2014/013639 WO2014120800A1 (en) | 2013-01-29 | 2014-01-29 | Spiro-lactam nmda receptor modulators and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506962A JP2016506962A (ja) | 2016-03-07 |
| JP2016506962A5 true JP2016506962A5 (OSRAM) | 2017-03-02 |
Family
ID=50071824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556106A Withdrawn JP2016506962A (ja) | 2013-01-29 | 2014-01-29 | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9708335B2 (OSRAM) |
| EP (1) | EP2951185B1 (OSRAM) |
| JP (1) | JP2016506962A (OSRAM) |
| KR (1) | KR20150110784A (OSRAM) |
| CN (1) | CN105308049A (OSRAM) |
| AU (1) | AU2014212501A1 (OSRAM) |
| BR (1) | BR112015018094A2 (OSRAM) |
| CA (1) | CA2899191A1 (OSRAM) |
| EA (1) | EA201591405A1 (OSRAM) |
| ES (1) | ES2618421T3 (OSRAM) |
| IL (1) | IL240164A0 (OSRAM) |
| MX (1) | MX2015009785A (OSRAM) |
| PE (1) | PE20151436A1 (OSRAM) |
| PH (1) | PH12015501598A1 (OSRAM) |
| SG (1) | SG11201505862TA (OSRAM) |
| WO (1) | WO2014120800A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0918868B8 (pt) | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| KR20150110787A (ko) * | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| TR201908596T4 (tr) | 2013-01-29 | 2019-07-22 | Aptinyx Inc | Spiro-laktam NMDA reseptörü modülatörleri ve bunların kullanımları. |
| SG11201505862TA (en) | 2013-01-29 | 2015-08-28 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| KR102410989B1 (ko) | 2013-01-29 | 2022-06-17 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| KR20150110586A (ko) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| EP3152213B1 (en) | 2014-06-04 | 2018-10-31 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists |
| EP3194403B1 (en) | 2014-09-15 | 2019-02-06 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| US10584127B2 (en) | 2015-06-01 | 2020-03-10 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists |
| US20210198315A1 (en) * | 2016-02-01 | 2021-07-01 | Naurex, INC | Process for synthesis of peptide compounds |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| KR102128675B1 (ko) | 2016-05-19 | 2020-06-30 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| AU2017306152A1 (en) * | 2016-08-01 | 2019-01-31 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| PE20190501A1 (es) * | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos |
| PE20190504A1 (es) * | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos |
| JP2019527235A (ja) * | 2016-08-01 | 2019-09-26 | アプティニックス インコーポレイテッド | スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用 |
| AU2017306136B2 (en) * | 2016-08-01 | 2021-10-21 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| MX2020008107A (es) | 2018-01-31 | 2020-09-25 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos. |
| WO2019152685A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and methods of using same |
| JP2021512109A (ja) * | 2018-01-31 | 2021-05-13 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 |
| WO2019152688A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2019152696A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| PH12021552839A1 (en) | 2019-06-14 | 2022-10-03 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| BR112021024117A2 (pt) | 2019-06-14 | 2022-03-22 | Janssen Pharmaceutica Nv | Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| CN111018746A (zh) * | 2019-12-16 | 2020-04-17 | 山东金城柯瑞化学有限公司 | 一种氨曲南主环合成中间体n-苄氧羰基-l-苏氨酸酰胺的合成方法 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
| US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
| EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
| US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| WO1992007561A1 (en) | 1990-10-30 | 1992-05-14 | Ss Pharmaceutical Co., Ltd. | Antiphlogistic and analgesic gel preparation |
| US5168103A (en) | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
| FR2692268B1 (fr) | 1992-06-15 | 1994-08-19 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations. |
| SE9301667D0 (sv) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
| US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
| US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
| US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
| US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| CN1130372C (zh) | 1996-06-07 | 2003-12-10 | 曾尼卡有限公司 | 肽衍生物 |
| WO1998005782A1 (en) | 1996-08-02 | 1998-02-12 | Zymogenetics, Inc. | Testis-specific insulin homolog polypeptides |
| US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
| JP3955345B2 (ja) | 1996-09-27 | 2007-08-08 | サントリー株式会社 | 新規アミノ酸ダイジハーベイン |
| AU1585999A (en) | 1997-11-12 | 1999-05-31 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
| US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
| US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| US6274314B1 (en) | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
| US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
| US6025471A (en) | 1998-06-03 | 2000-02-15 | Deghenghi; Romano | Diazaspiro, azepino and azabicyclo therapeutic peptides |
| AU1724000A (en) | 1998-11-12 | 2000-05-29 | Nyxis, Inc. | Diagnostic assay for cancer |
| US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
| AU1922301A (en) | 1999-11-17 | 2001-05-30 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
| US6521414B2 (en) | 2000-02-01 | 2003-02-18 | Agy Therapeutics, Inc. | Methods for identifying a modulator of the interaction of NMDA receptor with protein tyrosine phosphatase L1 |
| AU2001268467A1 (en) | 2000-06-14 | 2001-12-24 | Nyxis Neurotherapies, Inc. | Identification of genes and compounds for treatment of cancer |
| WO2001098367A2 (en) | 2000-06-22 | 2001-12-27 | Nyxis Neurotherapies, Inc. | Neuroactive peptides for treatment of hypoxia and related conditions |
| GB0018272D0 (en) | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
| EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
| IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
| US20020142287A1 (en) | 2000-12-14 | 2002-10-03 | Hirotaka Yamamoto | High throughput assay to detect inhibitors of the map kinase pathway |
| AU2002248553A1 (en) | 2001-03-07 | 2002-09-24 | Cognetix, Inc | Linear y-carboxyglutamate rich conotoxins |
| AU2002255705A1 (en) | 2001-03-12 | 2002-09-24 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
| US20030022253A1 (en) | 2001-07-25 | 2003-01-30 | Nyxis Neurotherapies, Inc. | Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby |
| DE60330456D1 (de) * | 2002-07-05 | 2010-01-21 | Targacept Inc | N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| CA2534909A1 (en) | 2003-08-08 | 2005-02-17 | The Burnham Institute | P16 mediated regulation of nmda receptors |
| US7662856B2 (en) | 2003-08-29 | 2010-02-16 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine |
| GB0323204D0 (en) * | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| CA2580020A1 (en) * | 2004-09-09 | 2006-03-23 | Ian M. Bell | Aryl spirolactam cgrp receptor antagonists |
| JP2008512481A (ja) * | 2004-09-13 | 2008-04-24 | メルク エンド カムパニー インコーポレーテッド | 二環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬 |
| US20060063707A1 (en) | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
| EP2030622B1 (en) | 2005-03-24 | 2011-02-23 | Emory University | Indication of dosage of progesterone in the treatment of a traumatic brain injury |
| US7951912B2 (en) | 2005-08-26 | 2011-05-31 | Wisconsin Alumni Research Foundation | Poly-β-peptides from functionalized β-lactam monomers and antibacterial compositions containing same |
| WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| MX2009002921A (es) | 2006-09-15 | 2009-04-01 | Schering Corp | Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico. |
| JP2008188285A (ja) | 2007-02-06 | 2008-08-21 | Bridgestone Corp | バックパッド及び車両用シート |
| CN101066945B (zh) | 2007-05-25 | 2010-05-19 | 中国科学院上海有机化学研究所 | 一种合成3-位取代内酰胺类化合物的方法 |
| CN101125817B (zh) | 2007-08-03 | 2011-09-14 | 中国科学院上海有机化学研究所 | 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法 |
| WO2009039390A2 (en) | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
| JP6078211B2 (ja) | 2008-02-20 | 2017-02-15 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | 自閉症および自閉症の表現型に関連する遺伝子変化ならびに自閉症の診断および治療に対するその使用方法 |
| KR101647520B1 (ko) | 2008-08-07 | 2016-08-10 | 에프. 호프만-라 로슈 아게 | 거대환식 화합물의 제조 방법 |
| BRPI0918868B8 (pt) | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| DE102009001460B4 (de) | 2009-03-11 | 2010-12-02 | Zf Friedrichshafen Ag | Ölbehälter |
| WO2011003064A2 (en) | 2009-07-02 | 2011-01-06 | Naurex, Inc. | Methods of treating neuropathic pain |
| RS53513B1 (sr) | 2009-10-05 | 2015-02-27 | Northwestern University | Glyx-13 za upotrebu u postupku tretiranja refraktornih depresija |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| CN102933226A (zh) | 2010-02-11 | 2013-02-13 | 西北大学 | 二级结构稳定化的nmda受体调节剂及其用途 |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| SG10202010665YA (en) | 2011-04-27 | 2020-11-27 | Univ Northwestern | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
| EP2723506B1 (en) | 2011-06-27 | 2017-02-15 | Koninklijke Philips N.V. | Ultrasound transducer assembly and method of manufacturing the same |
| TR201908596T4 (tr) | 2013-01-29 | 2019-07-22 | Aptinyx Inc | Spiro-laktam NMDA reseptörü modülatörleri ve bunların kullanımları. |
| KR20150110787A (ko) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| SG11201505862TA (en) | 2013-01-29 | 2015-08-28 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| KR102410989B1 (ko) | 2013-01-29 | 2022-06-17 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| KR20150110586A (ko) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
-
2014
- 2014-01-29 SG SG11201505862TA patent/SG11201505862TA/en unknown
- 2014-01-29 EP EP14703750.1A patent/EP2951185B1/en active Active
- 2014-01-29 MX MX2015009785A patent/MX2015009785A/es unknown
- 2014-01-29 PE PE2015001571A patent/PE20151436A1/es not_active Application Discontinuation
- 2014-01-29 US US14/764,426 patent/US9708335B2/en not_active Expired - Fee Related
- 2014-01-29 EA EA201591405A patent/EA201591405A1/ru unknown
- 2014-01-29 CN CN201480018644.1A patent/CN105308049A/zh active Pending
- 2014-01-29 JP JP2015556106A patent/JP2016506962A/ja not_active Withdrawn
- 2014-01-29 WO PCT/US2014/013639 patent/WO2014120800A1/en not_active Ceased
- 2014-01-29 KR KR1020157023269A patent/KR20150110784A/ko not_active Withdrawn
- 2014-01-29 BR BR112015018094A patent/BR112015018094A2/pt not_active IP Right Cessation
- 2014-01-29 AU AU2014212501A patent/AU2014212501A1/en not_active Abandoned
- 2014-01-29 ES ES14703750.1T patent/ES2618421T3/es active Active
- 2014-01-29 CA CA2899191A patent/CA2899191A1/en not_active Abandoned
-
2015
- 2015-07-20 PH PH12015501598A patent/PH12015501598A1/en unknown
- 2015-07-27 IL IL240164A patent/IL240164A0/en unknown
-
2017
- 2017-06-16 US US15/625,163 patent/US10316041B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506962A5 (OSRAM) | ||
| JP2016506961A5 (OSRAM) | ||
| JP2016506960A5 (OSRAM) | ||
| JP2016516043A5 (OSRAM) | ||
| JP2014511892A5 (OSRAM) | ||
| JP2016506959A5 (OSRAM) | ||
| JP2017526677A5 (OSRAM) | ||
| JP2014525420A5 (OSRAM) | ||
| JP2016513696A5 (OSRAM) | ||
| JP2014511891A5 (OSRAM) | ||
| JP2016512520A5 (OSRAM) | ||
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2018502877A5 (OSRAM) | ||
| JP2018524390A5 (OSRAM) | ||
| JP2015501833A5 (OSRAM) | ||
| JP2017528467A5 (OSRAM) | ||
| JP2015500843A5 (OSRAM) | ||
| JP2015520769A5 (OSRAM) | ||
| JP2013537203A5 (OSRAM) | ||
| JP2019500387A5 (OSRAM) | ||
| CY1114908T1 (el) | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες | |
| JP2014510147A5 (OSRAM) | ||
| CY1114318T1 (el) | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες | |
| JP2015522650A5 (OSRAM) | ||
| WO2008147557A3 (en) | Heteroaryl substituted thiazoles and their use as antiviral agents |